AxioNovo Pharma

AxioNovo Pharma is a specialty pharmaceutical company focused on the development and commercialization of innovative oncology supportive care products. The company's lead candidate, AXN-01, is a proprietary formulation of levoleucovorin, a folate analog used to enhance the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of various cancers. AxioNovo aims to optimize the delivery and efficacy of standard-of-care chemotherapy regimens, particularly for patients with colorectal and other gastrointestinal malignancies. By focusing on established molecules with proven clinical utility, the company seeks to reduce development risk while providing significant benefits to patients and healthcare providers. The leadership team consists of industry veterans with extensive experience in drug development and commercialization.